← All indications
Nasal Polyps
Focal accumulations of EDEMA fluid in the NASAL MUCOSA accompanied by HYPERPLASIA of the associated submucosal connective tissue. Polyps may be NEOPLASMS, foci of INFLAMMATION, degenerative lesions, or malformations.
Drugs by status
Approved for this indication (3)
Phase 4 trials (11)
Phase 3 trials (8)
Phase 2 trials (12)
Phase 1 trials (2)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (16)
- Merck
- GlaxoSmithKline
- National Heart, Lung, and Blood Institute (NHLBI)
- Harvard University
- Johns Hopkins University
- Loma Linda University
- Makassed General Hospital
- Northwestern University
- University of Dundee
- Recep Tayyip Erdogan University
- Sun Yat-Sen University
- Rize University
- University of Montreal
- University of Texas at Houston
- University of Western Ontario
- Government of Scotland
Organization Involved with Phase 3 Indications (25)
- Regeneron
- Bristol-Myers Squibb
- Roche
- AstraZeneca
- Sanofi
- Novartis
- Intersect ENT
- OptiNose AS
- Ain Shams University
- Eastern Virginia Medical School
- Emory University
- LifeBridge Health
- Shanxi Medical University
- University of Toronto
- Capital Medical University
- University of Chile
- Icahn School of Medicine at Mount Sinai
- Humanitas University
- Beijing Institute of Otolaryngology
- Advanced ENT and Allergy
- State University of New York, Brooklyn
- University of Sherbrooke
- BioClinica, Inc.
- Signant Health
- Ghent University
Organization Involved with Phase 2 Indications (12)
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (11)